

Biomarkers of Disease

An Evidence-based Approach

This new publication takes a critical, evidence-based look at the efficacy of new diagnostic tests which are increasingly being used to evaluate organ damage and dysfunction. The use of biomarkers is growing, with a steady stream of new products being brought out by the diagnostics industry. Some of these assist in diagnosis, while others provide a means of monitoring the state of progression of disease and the effectiveness of therapeutic options. However, in many cases, the evidence which supports the use of these new methods as opposed to traditional biochemical tests has not yet been demonstrated, and it is intended that this volume will help clarify the strengths and weaknesses of using these biomarkers across a wide range of applications and in the various organs of the body. This approach will provide clinicians, pathologists, clinical biochemists and medical laboratory scientists with an invaluable overview of the diverse applications of biomarkers in medicine.



Biomarkers of Disease

An Evidence-based Approach

Edited by

Andrew K. Trull, Lawrence M. Demers
David W. Holt, Atholl Johnston, J. Michael Tredger
and Christopher P. Price





PUBLISHED BY THE PRESS SYNDICATE OF THE UNIVERSITY OF CAMBRIDGE The Pitt Building, Trumpington Street, Cambridge, United Kingdom

CAMBRIDGE UNIVERSITY PRESS
The Edinburgh Building, Cambridge CB2 2RU, UK
40 West 20th Street, New York, NY 10011-4211, USA
477 Williamstown Road, Port Melbourne, VIC 3207, Australia
Ruiz de Alarcón 13, 28014 Madrid, Spain
Dock House, The Waterfront, Cape Town 8001, South Africa

http://www.cambridge.org

© Cambridge University Press 2002

This book is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2002

Printed in the United Kingdom at the University Press, Cambridge

Typeface Minion 8.5/12pt System QuarkXPress™ [se]

A catalogue record for this book is available from the British Library

ISBN 0 521 81102 3 hardback

Every effort has been made in preparing this book to provide accurate and up-to-date information which is in accord with accepted standards and practice at the time of publication. Nevertheless, the authors, editors and publisher can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors and publisher therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.



Contents

List of contributors

	Preface	xxi
Part 1	Assessing and utilizing the diagnostic or prognostic power of biomarkers	
1	Evidence-based medicine: evaluation of biomarkers R. Andrew Moore	3
2	Development of biomarkers: the industrial perspective Andy Bufton	16
3	Statistical approaches to rational biomarker selection Linda D. Sharples	24
4	Using intelligent systems in clinical decision support Richard Jones	32
Part 2	Biomarkers of kidney disease and dysfunction	
5	Biomarkers in renal disease Christopher P. Price	45
6	The genetics of renal disease Jean-Pierre Grünfeld, Bertrand Knebelmann	56
7	Early markers of nephrotoxicity for environmental and occupational monitoring Robert G. Price	66

V

page x



vi	Contents	
8	The early detection of renal impairment in diabetes mellitus. The case for microalbuminuria and other biomarkers Carl E. Mogensen	76
Part 3	Biomarkers of bone disease and dysfunction	
9	Bone turnover markers in clinical practice Richard Eastell, Sheila Hart	99
10	Biomarkers of bone formation Juha Risteli, Saila Kauppila, Arja Jukkola, Eevastiina Marjoniemi, Jukka Melkko, Leila Risteli	115
11	Biochemical markers of bone resorption Simon P. Robins	122
12	The clinical application of biomarkers in osteoporosis Patrick Garnero	133
13	Sources of preanalytical variability in the measurement of biochemical markers of bone turnover Markus J. Seibel	140
14	Genetic approaches to the study of complex diseases: osteoporosis Andre G. Uitterlinden	159
Part 4	Biomarkers of liver disease and dysfunction	
15	Biomarkers of hepatic disease Michael Oellerich	167
16	The immunogenetics of metabolic liver disease Peter T. Donaldson	177
17	Toxicogenetic markers of liver dysfunction J. Michael Tredger	190
18	Prognosis and management of patients with acute liver failure Fin Stolze Larsen	199
19	Biomarkers in artificial and bioartificial liver support Robin D. Hughes	211



vii	Contents	
20	Prognostic markers in liver disease Martin Burdelski	221
21	Apoptosis: biomarkers and the key role of mitochondria Kelvin Cain	228
22	Liver regeneration: mechanisms and markers Nelson Fausto, Jean Campbell	239
23	Determinants of responses to viruses and self in liver disease Michael P. Manns, Petra Obermayer-Straub	244
24	IL-6-type cytokines and signalling in inflammation Peter C. Heinrich, Johannes G. Bode, Lutz Graeve, Serge Haan, Astrid Martens, Gerhard Müller-Newen, Ariane Nimmesgern, Fred Schaper, Jochen Schmitz, Elmar Siewert	256
Part 5	Biomarkers of gastrointestinal disease and dysfunction	
25	Biomarkers in gastrointestinal disease Humphrey J. F. Hodgson	265
26	Tumour markers in gastrointestinal disease Anthony J. FitzGerald, Nicholas A. Wright	272
27	Markers of malabsorption: coeliac disease H. Julia Ellis, Jocelyn S. Fraser, Paul J. Ciclitira	281
Part 6	Biomarkers in toxicology	
28	Genomics and biomarkers in toxicology Jonathan D. Tugwood, Katherine M. Beckett	291
29	Protein profiling and proteomic databases Julio E. Celis, Pavel Gromov, Morten Østergaard, Hildur Pálsdóttir, Irina Gromova	299
30	Biomarkers for evaluating the safety of genetically modified foods Ad A. C. M. Peijnenburg, Hubert P. J. M. Noteborn, Harry A. Kuiper	313



viii	Contents	
Part 7	Biomarkers of cardiovascular disease and dysfunction	
31	The impact of biochemical tests on patient management Paul O. Collinson	325
32	Cardiac natriuretic peptides in risk assessment of patients with acute myocardial infarction or congestive heart failure Johannes Mair	334
33	Serum markers of inflammation and cardiovascular risk Juan Carlos Kaski	345
34	The clinical significance of markers of coagulation in acute coronary syndromes Lina Badimon, Antonio Bayés-Genís	355
35	Endothelin: what does it tell us about myocardial and endothelial dysfunction? John Pernow	365
36	Homocysteine: a reversible risk factor for coronary heart disease John C. Chambers	374
37	Matrix metalloproteinases and their tissue inhibitors Peter M. Timms, Stewart Campbell, Vinijar Srikanthan, Christopher P. Price	379
Part 8	Biomarkers of neurological disease and dysfunction	
38	Biomarkers of neurodegenerative disorders John M. Land	391
39	Traumatic brain injury: assessment by biochemical serum markers Tor Ingebrigtsen, Bertil Romner	398
40	An overview of S-100 $oldsymbol{eta}$ as a clinically useful biomarker of brain tissue damage John Azami, Basil F. Matta	406
Part 9	Biomarkers in transplantation	
41	Monitoring heart and lung transplant patients Marlene L. Rose	415



ix	Contents	
42	Monitoring liver transplant recipients Andrew Trull	423
43	Chronic allograft damage index as a surrogate marker for chronic allograft rejection Serdar Yilmaz, Mark Nutley, Eero Taskinen, Timo Paavonen, Pekka Hayry	433
44	Advances in pharmacodynamic biomarkers for monitoring the response to immunosuppressive drug therapy Victor W. Armstrong	442
45	The use of biomarkers for monitoring the response to immunosuppressive drug therapy Atholl Johnston	451
46	Post-transplantation bone disease Juliet E. Compston	461
47	Molecular diagnosis of cytomegalovirus disease Aycan F. Hassan-Walker, Vincent C. Emery, Paul D. Griffiths	467
48	Diagnosis and monitoring of inflammatory events in transplant recipients Claus Hammer, Gudrun Höbbel, Stephanie Hammer, Peter Fraunberger, Bruno Meiser	474
	Index	483



0521811023 - Biomarkers of Disease: An Evidence-Based Approach

Edited by Andrew K. Trull, Lawrence M. Demers, David W. Holt, Atholl Johnston, J. Michael Tredger and

Christopher P. Price

Frontmatter More information

Contributors

Victor W. Armstrong

Abteilung Klinische Chemie Zentrum Innere Medizin

Georg-August-Universität Göttingen

Robert-Koch-Strasse 40

Göttingen Germany

varmstro@med.uni-goettingen.de

John Azami

Addenbrooke's Hospital

Hills Road Cambridge CB2 2QQ UK

Lina Badimon

Cardiovascular Research Center IIBB/CSIC-HSCSP-UAB Jordi Girona, 18–26 08034 Barcelona

Spain

lbmucv@cid.csic.es

Antonio Bayés-Genís

Cardiovascular Research Center IIBB/CSIC-HSCSP-UAB Jordi Girona, 18–26 08034 Barcelona

Spain

Katherine M. Beckett

AstraZeneca Macclesfield Site Charterway

Silk Road Business Park

Macclesfield Cheshire SK10 2NA UK

Johannes G. Bode

Institute of Biochemistry

RWTH Aachen Pauweisstrasse 30 D-52074 Aachen Germany

Andy Bufton

Abbott Diagnostics Division

Abbott House Norden Road Maidenhead Berkshire SL6 4XF UK

andy.bufton@abbott.com

Martin Burdelski

Department of Paediatrics University Hospital Hamburg

Eppendorf Martinistrasse 52

X



0521811023 - Biomarkers of Disease: An Evidence-Based Approach

Edited by Andrew K. Trull, Lawrence M. Demers, David W. Holt, Atholl Johnston, J. Michael Tredger and

Christopher P. Price Frontmatter

More information

xi List of contributors

D-20246 Hamburg

Germany

burdelsk@uke.uni-hamburg.de

Kelvin Cain

MRC Toxicology Unit Hodgkin Building University of Leicester

Lancaster Road Leicester LE1 9HN

UK

kc5@leicester.ac.uk

Jean Campbell

Department of Pathology

University of Washington School of

Medicine Seattle WA 98195 USA

Stewart Campbell

Department of Clinical Biochemistry St Bartholomew's and The Royal London

Hospitals West Smithfield London

EC1A 7BE UK

Julio E. Celis

Department of Medical Biochemistry and Danish Centre for Human Genome

Research

University of Aarhus Ole Worms Allé Building 170 DK-800 Aarhus C Denmark

jec@biokemi.aau.di

John C. Chambers

National Heart and Lung Institute

Hammersmith Hospital

Du Cane Road London W12 0NN

jchambers@eht.org.uk

Paul J. Ciclitira

UK

Gastroenterology Unit The Rayne Institute (KCL) St Thomas' Hospital Lambeth Palace Road

London SE1 7EH UK

Paul O. Collinson

St George's Hospital and Medical School

St George's Hospital Cranmer Terrace

London SW17 0BE UK

poctrop@poctrop.demon.co.uk

Juliet E. Compston

Department of Medicine

Level 5 Box 157

Addenbrooke's Hospital

Cambridge CB2 2QQ UK

jec1001@cam.ac.uk

Laurence M. Demers

Pennsylvania State University College of

Medicine

The M.S. Hershey Medical Center

500 University Drive

Hershey PA 17033 USA



0521811023 - Biomarkers of Disease: An Evidence-Based Approach

Edited by Andrew K. Trull, Lawrence M. Demers, David W. Holt, Atholl Johnston, J. Michael Tredger and Christopher P. Price

Frontmatter

More information

xii List of contributors

Peter T. Donaldson

Centre for Liver Research

The School of Clinical Medical Sciences

University of Newcastle Newcastle upon Tyne

NE2 4HH UK

p.t.donaldson@ncl.ac.uk

Richard Eastell

Division of Clinical Science (NGHT)

Section of Medicine Bone Metabolism Group Northern General Hospital

Herries Road Sheffield S5 7AU UK

r.eastell@sheffeld.ac.uk

H. Julia Ellis

Gastroenterology Unit
The Rayne Institute (KCL)
St Thomas' Hospital
Lambeth Palace Road

London SE1 7EH UK

julia.ellis@kcl.ac.uk

Vincent C. Emery

Department of Virology

Royal Free and University College Medical

School

Rowland Hill Street

London NW3 2PF UK Nelson Fausto

Department of Pathology

University of Washington School of

Medicine Seattle WA 98195 USA

nfausto@u.washington.edu

Anthony J. FitzGerald

Department of Histopathology

Hammersmith Hospital

Du Cane Road London W12 0NN

UK

Jocelyn S. Fraser

Gastroenterology Unit The Rayne Institute (KCL) St Thomas' Hospital Lambeth Palace Road

London SE1 7EH UK

Peter Fraunberger

Institute of Clinical Chemistry

Klinikum Grosshadern LM-University of Munich

Munich Germany

Patrick Garnero

Unité INSERM 403 Hôpital E Herriot

Pavillion F

69437 Lyon Cedex 03

France

Patrick.garnero@synarc.com



0521811023 - Biomarkers of Disease: An Evidence-Based Approach

Edited by Andrew K. Trull, Lawrence M. Demers, David W. Holt, Atholl Johnston, J. Michael Tredger and

Christopher P. Price

Frontmatter More information

xiii List of contributors

Lutz Graeve

Institute of Biochemistry

RWTH Aachen Pauweisstrasse 30 D-52074 Aachen Germany

Paul D. Griffiths

Department of Virology

Royal Free and University College Medical

School

Rowland Hill Street

London NW3 2PF UK

Pavel Gromov

Department of Medical Biochemistry

University of Aarhus Ole Worms Allé Building 170 DK-800 Aarhus C

Denmark

Irina Gromova

Department of Medical Biochemistry

University of Aarhus Ole Worms Allé Building 170 DK-800 Aarhus C Denmark

Jean-Pierre Grünfeld

Service de Néphrologie

Hôpital Necker 161 rue de Sèvres 75743 Paris Cedex 15

France

jean-pierre.grunfeld@nck.ap-hp-paris.fr

Serge Haan

Institute of Biochemistry

RWTH Aachen Pauweisstrasse 30 D-52074 Aachen Germany

Claus Hammer

Institute of Surgical Research Klinikum Grosshadern LM-University of Munich

Munich Germany

Hammer@icf.med.uni-muenchen.de

Stephanie Hammer

Institute of Surgical Research Klinikum Grosshadern LM-University of Munich

Munich Germany

Sheila Hart

Division of Clinical Science (NGHT)

Section of Medicine Bone Metabolism Group Northern General Hospital

Herries Road Sheffield S5 7AU UK

Aycan F. Hassan-Walker

Department of Virology

Royal Free and University College Medical

School

Rowland Hill Street

London NW3 2PF

aycan@rfhsm.ac.uk



0521811023 - Biomarkers of Disease: An Evidence-Based Approach

Edited by Andrew K. Trull, Lawrence M. Demers, David W. Holt, Atholl Johnston, J. Michael Tredger and Christopher P. Price

Frontmatter

More information

xiv List of contributors

Pekka Hayry

Transplantation Laboratory PO Box 21 (Haartmaninkatu 3)

00014 University of Helsinki Helskinki

Finland

pekka.hayry@helsinki.fi

Peter C. Heinrich

Institute of Biochemistry

RWTH Aachen Pauweisstrasse 30 D-52074 Aachen

Germany

heinrich@rwth-aachen.de

Gudrun Höbbel

Institute of Surgical Research Klinikum Grosshadern

LM-University of Munich

Munich Germany

David W. Holt

The Analytical Unit

St George's Hospital Medical School

London SW17 0BE UK

Robin D. Hughes

Institute of Liver Studies

Guy's, King's and St Thomas' School of

Medicine Bessemer Road London

SE5 9PJ

robin.hughes@kcl.ac.uk

Humphrey J. F. Hodgson

Royal Free and University College School of

Medicine

Rowland Hill Street

London NW3 2PF UK

h.hodgson@rfc.ucl.ac.uk

Tor Ingebrigtsen

Department of Neurosurgery

Tromsø University Hospital

N-9038 Tromsø

Norway

tor.ingebrigtsen@rito.no

Atholl Johnston

Clinical Pharmacology

St Bartholomew's Hospital and the Royal

London School of Medicine and

Dentistry

Charterhouse Square

London EC1M 6BQ

UK

A.Johnston@mds.qmw.ac.uk

Richard Jones

Directorate of Pathology

Leeds Teaching Hospitals NHS Trust and

University of Leeds

Leeds LS1 3EX UK

r.g.jones@leeds.ac.uk

Arja Jukkola

Department of Clinical Chemistry,

Oncology and Pathology

University of Oulu PO Box 5000

FIN-90014 University of Oulu

Oulu Finland



0521811023 - Biomarkers of Disease: An Evidence-Based Approach

Edited by Andrew K. Trull, Lawrence M. Demers, David W. Holt, Atholl Johnston, J. Michael Tredger and

Christopher P. Price

Frontmatter More information

xv List of contributors

Juan Carlos Kaski

Coronary Artery Disease Unit

Department of Cardiological Sciences

St George's Hospital Medical School

Cranmer Terrace

London

SW17 0BE

UK

jkaski@sghms.ac.uk

Saila Kauppila

Department of Clinical Chemistry,

Oncology and Pathology

University of Oulu

PO Box 5000

FIN-90014 University of Oulu

Oulu

Finland

Bertrand Knebelmann

Service de Néphrologie

Hôpital Necker

161 rue de Sèvres

75743 Paris Cedex 15

France

Harry A. Kuiper

RIKILT (National Institute for Quality

Control of Agricultural Products)

Wageningen University and Research

Centre

Wageningen

The Netherlands

John M. Land

Neurometabolic Unit

Institute of Neurology and National

Hospital

Queen Square

London

UK

iland@ion.ucl.ac.uk

Fin Stolze Larsen

Department of Haematology

Rigshospitalet

Copenhagen University Hospital

Copenhagen

Denmark

stolze@post3.tele.dk

Johannes Mair

Department of Internal Medicine

Division of Cardiology

University of Innsbruck

Anichstrasse 35

A-6020 Innsbruck

Austria

Johannes.Mair@uibk.ac.at

Michael P. Manns

Department of Gastroenterology and

Hepatology

Medical School of Hannover

Carl-Neuberg Strasse 1

D-30625 Hannover

Germany

manns.michael@mh-hannover.de

Eevastiina Marjoniemi

Department of Clinical Chemistry,

Oncology and Pathology

University of Oulu

PO Box 5000

FIN-90014 University of Oulu

Oulu

Finland

Astrid Martens

Institute of Biochemistry

RWTH Aachen

Pauweisstrasse 30

D-52074 Aachen

Germany



0521811023 - Biomarkers of Disease: An Evidence-Based Approach

Edited by Andrew K. Trull, Lawrence M. Demers, David W. Holt, Atholl Johnston, J. Michael Tredger and Christopher P. Price

Frontmatter

More information

xvi List of contributors

Basil F. Matta

Perioperative Care Services Addenbrooke's Hospital

Hills Road Cambridge CB2 2QQ UK

basil@bmatta.demon.co.uk

Bruno Meiser

Department of Cardiothoracic Surgery

Klinikum Grosshadern LM-University of Munich

Munich Germany

Jukka Melkko

Department of Clinical Chemistry,

Oncology and Pathology

University of Oulu PO Box 5000

FIN-90014 University of Oulu

Oulu Finland

Carl E. Mogensen

Medical Department M Aarhus Kommunehospital Aarhus University Hospital

DK-800 Aarhus Denmark

akh.grpozs.com@aaa.dk

R. Andrew Moore

Pain Research and Nuffield Department of

Anaesthetics The Churchill Oxford OX3 7LJ UK

andrew.moore@pru.ox.ac.uk

Gerhard Müller-Newen

Institute of Biochemistry

RWTH Aachen Pauweisstrasse 30 D-52074 Aachen Germany

Ariane Nimmesgern

Institute of Biochemistry

RWTH Aachen Pauweisstrasse 30 D-52074 Aachen Germany

Hubert P. J. M. Noteborn

RIKILT (National Institute for Quality Control of Agricultural Products)

Wageningen University and Research Centre

Wageningen The Netherlands

Mark Nutley

Department of Surgery

University of Calgary and Foothills Medical

Centre Calgary Alberta Canada

Petra Obermayer-Straub

Department of Gastroenterology and

Hepatology

Medical School of Hannover Carl-Neuberg Strasse 1 D-30625 Hannover

Germany

Michael Oellerich

Abteilung Klinische Chemie Zentrum Inner Medizin Georg-August-Universtät

Göttingen Germany

moeller@med.uni-goettingen.de



0521811023 - Biomarkers of Disease: An Evidence-Based Approach

Edited by Andrew K. Trull, Lawrence M. Demers, David W. Holt, Atholl Johnston, J. Michael Tredger and

Christopher P. Price Frontmatter

More information

xvii List of contributors

Morten Østergaard

Department of Medical Biochemistry

University of Aarhus Ole Worms Allé Building 170 DK-800 Aarhus C Denmark

Timo Paavonen

Transplantation Laboratory PO Box 21 (Haartmaninkatu 3) 00014 University of Helsinki

Helskinki Finland

Hildur Pálsdóttir

Department of Medical Biochemistry

University of Aarhus Ole Worms Allé Building 170 DK-800 Aarhus C Denmark

Ad A. C. M. Peijnenburg

RIKILT (National Institute for Quality Control of Agricultural Products)

Wageningen University and Research Centre

Wageningen
The Netherlands

A.A.C.M.Peijnenburg@rikilt.dlo.nl

John Pernow

Department of Cardiology Karolinska Hospital S-171 76 Stockholm

Sweden

jpw@cardio.ks.se

Christopher P. Price

Bayer Diagnostics Division

Stoke Court Stoke Poges Berks SL2 4LY UK

c.p.price@mds.qmw.ac.uk

Robert G. Price

Division of Life Sciences King's College London 150 Stamford Street

London SE1 8WA UK

r.price@kcl.ac.uk

Juha Risteli

Department of Clinical Chemistry,

Oncology and Pathology

University of Oulu PO Box 5000

FIN-90014 University of Oulu

Oulu Finland

juha.risteli@oulu.fi

Leila Risteli

Department of Clinical Chemistry,

Oncology and Pathology

University of Oulu PO Box 5000

FIN-90014 University of Oulu

Oulu Finland



0521811023 - Biomarkers of Disease: An Evidence-Based Approach

Edited by Andrew K. Trull, Lawrence M. Demers, David W. Holt, Atholl Johnston, J. Michael Tredger and

Christopher P. Price

Frontmatter More information

xviii List of contributors

Simon P. Robins

Skeletal Research Unit

Rowett Research Institute

Bucksburn

Aberdeen

AB21 9SB

UK

S.Robins@rri.sari.ac.uk

Bertil Romner

Department of Neurosurgery

Lund University Hospital

S-22 185 Lund

Sweden

bertil.romner@neurokir.lu.se

Marlene L. Rose

National Heart and Lung Institute

Heart Science Centre

Harefield Hospital

Harefield

Middlesex

UB9 6IH

UK

marlene.rose@harefield.nthames.nhs.uk

Fred Schaper

Institute of Biochemistry

RWTH Aachen

Pauweisstrasse 30

D-52074 Aachen

Germany

Jochen Schmitz

Institute of Biochemistry

RWTH Aachen

Pauweisstrasse 30

D-52074 Aachen

Germany

Markus J. Seibel

University of Sydney

Department of Endochinology and

Metabolism C64

Level 6 - Medical Centre

Concord Hospital

Sydney

2139 NSW

Australia

Markus.Seible@

email.cs.nsw.gov.au

Linda D. Sharples

MRC Biostatistics Unit

University Forvie Site

Robinson Way

Cambridge

CB4 3EU

UK

linda.sharples@mrc-bsu.cam.ac.uk

Elmar Siewert

Institute of Biochemistry

RWTH Aachen

Pauweisstrasse 30

D-52074 Aachen

Germany

Vinijar Srikanthan

Department of Clinical Biochemistry

St Bartholomew's and The Royal London

Hospitals

West Smithfield

London

EC1A 7BE

IJK

Eero Taskinen

Transplantation Laboratory

PO Box 21 (Haartmaninkatu 3)

00014 University of Helsinki

Helskinki

Finland



xix List of contributors

Peter M. Timms

Department of Clinical Biochemistry St Bartholomew's and The Royal London Hospitals

West Smithfield

London EC1A 7BE

UK

p.m.timms@mds.qmw.ac.uk

J. Michael Tredger

Institute of Liver Studies

Guy's, King's and St Thomas' School of

Medicine

Bessemer Road

London SE5 9PJ UK

michael.tredger@kcl.ac.uk

Andrew K. Trull

Department of Pathology Papworth Hospital Papworth Everard

Cambridge CB3 8RE UK

And rew. Trull @papworth-tr. anglox.nhs. uk

Jonathan D. Tugwood

AstraZeneca

Macclesfield Site

Charterway

Silk Road Business Park

Macclesfield Cheshire

SK10 2NA

UK

jonathan.tugwood@astrazeneca.com

Andre G. Uitterlinden

Department of Internal Medicine/ Department of Epidemiology and

Biostatistics

Erasmus University Medical School

Rotterdam
The Netherlands

uitterlinden@endov.fgg.eur.nl

Nicholas A. Wright

Histopathology Unit

Imperial Cancer Research Fund

Hammersmith Hospital 44 Lincoln Inn Fields

London WC2A 3PX

UK

n.wright@ic.ac.uk

Serdar Yilmaz

Division of Transplantation

Department of Surgery

University of Calgary and Foothills Medical

Centre

Calgary

Alberta

Canada



Preface

Biological markers or 'biomarkers' of organ damage and dysfunction occupy a central position in the armamentarium of the clinician that is used for the screening, diagnosis and management of disease. Our knowledge of the pathophysiological basis of individual diseases continues to increase inexorably and the discoveries emanating from the Human Genome Project are set to enhance this knowledge immeasurably. Understanding the aetiopathogenesis of changes that take place in individual tissues, organs or compartments of the body can help in the search for markers that reflect these changes. Some of these changes may be directly related to the pathological abnormality while others might be a secondary consequence of the abnormality.

Basic research into the pathophysiology of a disease provides the foundation of knowledge that can lead to the discovery of valuable biomarkers. This foundation can also act as the starting point for the discovery of pharmaceutical interventions. Increasingly, with a more systematic approach to biomarker development and drug discovery, we are seeing the measurement of the biomarker playing a greater role in monitoring the efficacy and/or side effects of the therapeutic intervention. From a clinical standpoint, this can have a major benefit in assessing compliance with therapy, which is acknowledged to be one of the key determinants of efficacy, especially when there is no other ready means to judge the patient's response.

The discovery of a new biomarker is complemented by the development and validation of appropriate analytical technology. The appropriateness can be viewed in relation to a number of performance characteristics and the mode of delivery. Thus, the test may be delivered on an automated analytical platform from a centralized laboratory facility or by means of a point of care testing device. The ability to deliver the test at the point of care, with the immediacy of response, may be a key factor in ensuring the clinical utility of the test. The basic analytical characteristics include imprecision and inaccuracy which, together with the issues surrounding the biological variation and stability of the biomarker, constitute the core components of technical performance.

The diagnostic performance of the test must then be established by comparing biomarker measurements in appropriate populations of patients and controls in

xxi



xxii Preface

the relevant clinical setting. A diagnostic test is one element of a process which begins with a clinical question; the ideal test is one which provides an unequivocal answer to the question and enables a decision to be made on what action must be taken next. When effective action is then taken, a positive outcome or benefit can accrue to the patient, the healthcare system and society as a whole. Unfortunately, few tests are ideal in this respect and the medical practitioner usually has to appreciate the limited diagnostic performance of a test in order to make a balanced interpretation of the results in the context of the patient's clinical status.

The above description of the technical and clinical validation of a test applies to most research into diagnostic tests today. However, this is not the end of the process, as it is also necessary to consider the decision-making process associated with the introduction of a new test into the routine laboratory. In order to justify investment – from a clinical, operational and economic standpoint – it is not only important to prove that the test meets required standards of diagnostic performance but also that it delivers a positive clinical, operational or economic outcome – and, preferably, all three! Incorporating these outcome metrics into the evaluation of laboratory diagnostics provides a more rigorous and holistic standard of healthcare than is often embraced by laboratory medicine and illustrates the importance of integrating laboratory medicine fully into clinical practice – in terms of investment, delivery and quality management.

This book is the first attempt to review the current literature on biomarkers from an evidence-based and clinical outcomes perspective. It represents a distillation of the presentations made at the 'EMBODY 2000' conference held in Cambridge, England. It covers selected key areas – a comprehensive book would have necessitated a whole textbook! However, each of the authors, all clinical scientists of international repute, was asked to review the literature in their chosen field from the perspective of the impact of biomarkers on clinical outcome. We hope that this initiative, both the meeting and the book, represents a watershed in the literature on biomarkers, focusing more attention on clinical outcomes.

It is self-evident, but still worth stating, that a positive outcome will not be achieved unless the right test is requested in the first instance and the result acted upon with the relevant therapeutic strategy. This book, therefore, is not only relevant to professionals in laboratory medicine but also to the users of biomarkers.

Andrew K. Trull
Laurence M. Demers
David W. Holt
Atholl Johnston
J. Michael Tredger
Christopher P. Price